Tivozanib (Fotivda) is an oral kinase inhibitor and belongs to the category of targeted therapeutic drugs. As a new-generation vascular endothelial growth factor receptor (VEGFR) inhibitor, this medication plays an important role in the treatment of advanced renal cell carcinoma.
What Kind of Drug Is Tivozanib (Fotivda)?
Pharmacological Properties
Tivozanib is a potent tyrosine kinase inhibitor. Pharmacological studies have shown that it can specifically inhibit the phosphorylation of VEGFR-1, VEGFR-2, and VEGFR-3.
In preclinical studies, this drug effectively inhibits the growth of various tumors, including renal cell carcinoma, by suppressing angiogenesis and reducing vascular permeability.
The drug is mainly metabolized by the CYP3A4 enzyme, with an elimination half-life of approximately 111 hours, indicating a long duration of action in the body.
Indication Scope
Tivozanib is explicitly approved for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC).
This drug is suitable for patient populations who have received two or more prior systemic treatment regimens.
The limitation of this indication reflects its important position in the advanced stage of treatment.
Specifications and Properties of Tivozanib (Fotivda)
Appearance Identification Features
The 1.34 mg capsule has an all-yellow opaque design. The capsule cap is printed with "TIVZ" in dark blue, and the capsule body is marked with "SD" in dark blue.
The 0.89 mg capsule adopts a two-color design with a dark blue capsule cap and a yellow capsule body. The capsule cap is printed with "TIVZ" in yellow, and the capsule body is marked with "LD" in dark blue.
Ingredient Composition Analysis
The active pharmaceutical ingredient is tivozanib hydrochloride. Each 1.34 mg capsule contains 1.5 mg of tivozanib hydrochloride (equivalent to 1.34 mg of tivozanib), and each 0.89 mg capsule contains 1.0 mg of tivozanib hydrochloride (equivalent to 0.89 mg of tivozanib).
The excipient system includes mannitol and magnesium stearate. The capsule shell is composed of ingredients such as gelatin, titanium dioxide, and FDA Yellow Iron Oxide.
Storage Conditions and Medication Standards for Tivozanib (Fotivda)
Environmental Control Requirements
The medication should be stored at a standard room temperature of 20°C to 25°C (68°F to 77°F), with short-term storage allowed within the range of 15°C to 30°C (59°F to 86°F).
This strict temperature control requirement ensures the stability of the drug’s chemical structure.
Precautions for Use
The medication must be swallowed whole; do not open the capsule. It is recommended to take it with a sufficient amount of water, either before or after meals.
If a dose is missed, skip that dose and continue taking the medication at the next regular administration time. Under no circumstances should a double dose be taken on the same day.
